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Anion-exchange chromatography of solubilized pig liver cell membranes on DEAE-Sepharose gave a fraction with high affinity binding proteins 
for VIP and glucagon distinct from each other. Scatchard analysis indicated the presence of one binding site for VIP (& 1.5 +- 0.6 nM and B,,,,, 
1.3 1: 0.4 pmol/mg). The order of potency for VIP-related peptides to inhibit [‘251]VIP binding was: VIP > peptide histidine isoleucine amide (PHI) 
> rat growth hormone releasing factor (rGRF) > secretin. GTP-y-S inhibited [‘*‘I]VIP binding and reduced the affinity of VIP binding sites to 
6.5 nM. In the same isolated fraction, [“51]glucagon binding was displaced by glucagon preferentially to oxyntomodulin, and GTP did not affect 
this [“‘I]glucagon binding. Scatchard analysis indicated the presence of one binding site for glucagon (& 0.08 + 0.03 nM and B,,, 0.31 f 0.01 
pmol/mg). A low-affinity VIP binding protein (IC,, 0.7 PM) was detected m a fraction eluting later and exhibited a peptide specificity: rGRF > 
VIP > VIP(lO-28) > secretin > PHI. This rGRF-preferring protein (18 kDa) was purified and had a partial amino-acid sequence identical to that 
of calmodulin. Its [“‘I]VIP binding was competitively inhibited by VIP and calmidazolium in a manner similar to that for pig brain calmodulin. 
Thus we have co-solubilized VIP and glucagon high affinity receptors from pig liver cell membranes and separated them from VIP-binding 
calmodulin. 
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1. INTRODUCTION 
Vasoactive intestinal polypeptide (VIP) is a neu- 
ropeptide that exhibits several biological activities in 
many tissues and organs [l]. In liver, VIP and the struc- 
turally related peptide glucagon stimulate hepatic glyco- 
genolysis and gluconeogenesis [2]. The role of glucagon 
in regulating glucose metabolism has been clearly estab- 
lished and recent reports suggest hat cell-mediated me- 
tabolism of receptor bound glucagon may be linked to 
hepatic glucagon processing [3]. Interestingly, C-termi- 
nal fragments of glucagon (19-29, 18-29), resulting 
from the interaction of glucagon and liver cells, inhibit 
the hepatic Ca2+ pump [4]. Much evidence suggests that 
VIP and glucagon actions depend on the presence of 
functional receptors [5] and liver cell membranes repre- 
sent a rich source of both receptors [6.7], which can be 
extracted by CHAPS in an active form [8-121. These 
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findings suggested the possibility of a simultaneous ol- 
ubilization of VIP and glucagon receptors from liver cell 
membranes. However, detergent reatment of VIP re- 
ceptors may lead to an altered peptide specificity and 
lowered affinity for VIP [13,14]. Furthermore, hepatic 
proteases against VIP and glucagon may be present in 
solubilized extracts [ 111. 
We now report the co-solubilization from pig liver 
cell membranes of active VIP and glucagon receptors, 
with retained high affinity for the ligands, peptide spec- 
ificity, and separation from a low affinity VIP-binding 
protein apparently identical to calmodulin. 
2. MATERIALS AND METHODS 
2.1. Materials 
(3-[“51]tyrosyl’o)VIP and (3-[‘ZSI]tyrosy1’0)glucagon wereobtained 
from Amersham and are referred to as [“‘I]VIP and [‘Z51]glucagon, 
glucagon was obtained from Novo (Bagsvaerd, Denmark), synthetic 
rat growth hormone releasing factor (rGRF). human glucagon-like 
peptide- (GLP-2). human glucagon-like peptide-l (GLP-1(7-36)) 
amide and VIP(lO-28) from Peninsula (Merseyside, UK). CHAPS, 
leupeptin, pepstatin and GTP-y-S, pig brain calmodulin and calmi- 
dazolium from Boehringer (Mannheim, Germany), bacitracin and 
bovine serum albumin from Sigma, disuccinimidyl suberate from 
Pierce (Rockford, IL, USA), and wheat germ agglutinin from IBF 
(Villeneuve-la-Garenne, France). Oxyntomodulin was a gift from Dr. 
D. Bataille, CCIPE. Montpellier, France. VIP, peptide histidine 
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isoleucine amide (PHI) and secretin were isolated from pig upper 
intestine, as described [15-171. 
2.2. Preparation of pig liver cell membranes 
Crude pig liver membranes were prepared according to [18] with a 
homogenizing buffer of 10 mM triethanolamine (pH 7.8) 0.25 M 
sucrose, 5 mM MgCI,, 2.5 mM EDTA and 0.1 mM phenylmethylsul- 
fonyl fluoride. The final pellet was washed twice with 5 mM HEPES- 
KOH (pH 8.0) and 25 mM Tris-HCl (pH 7.5), respectively. and kept 
at -80°C until use. Protein concentration was determined with the 
BCA reagent from Pierce (Rockford, IL. USA) and bovine serum 
albumin was used as standard. 
2.3. Solubdizatlon of membrane proteins 
Pig liver cell membranes were suspended (5 mg protein/ml; 25 mM 
Tris-HCI, pH 7.7, with 0.4% CHAPS, 25% glycerol, 5 mM MgC1, and 
0.1 mM phenylmethylsulfonyl fluoride) and stirred for 20 min at 4°C. 
After centrifugation (100,000 x g for 30 min) the supernatant was 
filtered through 0.45 pm Millipore filters and stored at -80°C. 
2.4. Binding studies 
CHAPS solubilized extracts (So-250 ~1) were incubated with 
[‘251]VIP (2&50 PM) in the presence or absence of unlabeled VIP in 
50 mM Tris-HC1 (pH 7.5) 2 mM MgC&, 0.3% bovine serum albumin 
and 0.01% bacitracin in a final volume of 400@. After 30 min at 20°C. 
receptor-bound [‘251]VIP was separated from free ligand by addition 
of 1.5 ml ice-cold dextran-coated charcoal (0.5% Norit A and 0.05% 
Dextran T-70). followed by centrifugation at 2,500 x g for 5 mm. The 
radioactivity present in the collected supernatant was counted in a 
gamma-counter. The binding of [“51]glucagon (20-50 PM) to CHAPS 
solubilized extracts (50-200~1) in the presence or absence of unlabeled 
glucagon was measured at 4°C for 12 h, final volume 400 ~1, assay 
buffer 50 mM Tris-HC1 (pH 7.5), 0.1% bovine serum albumm, 0.01% 
bacitracin, 0.1 mM phenylmethylsulfonyl fluoride, 1 PM leupeptm, 1 
PM pepstatin. The [‘ZSI]glucagon-receptor complex was separated 
from free ligand using dextran-coated charcoal. The non-specific bmd- 
ing measured in the presence of 1 PM unlabeled VIP or glucagon was 
subtracted to obtain specific binding and corresponded to about 10% 
of the total radioactivity. 
2.5. DEAE chromatography of CHAPS-solubilized membrane proteins 
The solubilized liver membrane extract (1,000 ml) was applied to a 
column (5 x 20 cm) of DEAE-Sepharose Cl-6B, equilibrated at 4°C 
with 20 mM Tris-HCI (pH 8.0) 40 mM NaCI, 20% glycerol and 0. I % 
CHAPS, at a flow rate of 130 ml/h. Adsorbed proteins were eluted 
with a gradient of NaCl in the equilibrating buffer. Aliquots of 100 
~1 from 12 ml fractions were assayed for [“‘I]VIP and [“51]glucagon 
binding. Fractions containing VIP- and glucagon-binding activities 
were termed A, B, C and D according to their elution order and stored 
at -80°C. 
2.6. Wheat germ agglutinin-affinity rhromatogra@: 
Two ml of agarose-bound wheat germ agglutmm in a chromato- 
graphic tube (1.1 x 10 cm) was equilibrated in 50 mM Tris-HC1 (pH 
7.5). 20% glycerol and 0.1% CHAPS. Two-ml samples were mixed 
with the gel for 12 h at 4°C. After washing with 5 vols. equilibration 
buffer, adsorbed glycoproteins were eluted with 5 vols. of the buffer 
containing 0.3 M N-acetyl-o-glucosamine. Aliquots (250 ~1 from frac- 
tions of 2 ml) were assayed for [‘251]VIP and [“51]glucagon binding 
activities. 
2.7. Cross linking and SDS-PAGE analysis 
Cross-linking studies were performed with DEAE-purified fraction 
D (Fig. 1). [‘251]VIP (0.1 nM) was incubated with 100 ~1 of fraction 
D in the presence or absence of unlabeled VIP under the binding 
conditions described above. Samples were cross-linked with disuccin- 
imidyl suberate (25 mM in dimethyl sulfoxide), which was added at 
a final concentration of 0.5 mM. After 15 min on ice, the reaction was 
quenched with 30 mM glycine. 
36 
A fivefold concentrated sample buffer was added to cross-hnked 
incubates to obtain a final sample buffer of 50 mM Tris-HCI (pH 6.8). 
10% glycerol and 2% (w/v) SDS. The samples were heated at 60°C for 
20 min before SDS-PAGE analysis [19] with a 4% acrylamide stackmg 
gel and IO-15% acrylamide resolving gel. Stained and destained gels 
were dried and exposed to Fuji X-ray film with an intensifying screen 
(Kyokko BX-III) at -80°C for 5510 days. 
2.8. Purification of a low affinity binding protem for VIP 
Fraction D (120 ml) was concentrated in a Diaflo cell (cut-off filter 
10.000 MW, Millipore) to 10 ml and applied to Sephacryl S-100 HR 
(2.6 x 63 cm). equilibrated in 25 mM Tris-HCI (pH 7.6). 25 mM NaCl 
and 0.1% CHAPS. Fractions of 5.5 ml were collected at a flow rate 
of 130 ml/h. Aliquots of 1OOfil were assayed for specific binding. The 
active fractions were pooled and incubated with 5 ml VIP-affinity gel. 
prepared by coupling 0.4 prnol VIP per ml CNBr-activated agarose. 
according to the manufacturer’s protocol (Pharmacia, Sweden), and 
equilibrated in 50 mM Tris-HCl (pH 7.5). 0.1% CHAPS. After 5 h of 
incubation at 4”C, the gel was poured into a chromatographic tube 
(1 x 7 cm) and washed with 5 ~01s. buffer. Bound proteins were eluted 
with buffer containing 0.2 M NaCl and fractions with [“51]VIP bmd- 
ing activity concentrated using Centricon- microconcentrators to a 
final volume of 0.5 ml. This sample was diluted with 0.5 ml 20 mM 
Tris-HCI (pH 7.0). 0.1% CHAPS and chromatographed on Mono Q 
515 at a flow of 1 ml/min. The [“51]VIP binding fraction was eluted 
with increasing concentrations of NaCl. The [“51]VIP binding protein 
was subjected to enzymatic hydrolysis with endoproteinase Lys-C as 
described [20]. The fragments were separated by HPLC on reverse- 
phase C,, Vydac (4.6 x 250 mm, Hesperia. CA, USA) at a flow rate 
of 1 ml/mm using a linear gradient of acetonitrile/O. 1% trifluoroacetic 
acid (O-60% in 45 min). Edman degradation of the major fragment 
recovered was performed with an ABI 477A protein sequencer and 
on-line phenylthiohydantoin analysis. The protein sequence was com- 
pared against the NBRF protein data bank (release 23) using the 
program FASTA [21]. Binding studies were performed as described 
above except that 1 mM CaClz was included mto the buffer. 
3. RESULTS 
3.1. Solubilization of VIP and glucagon binding sites 
with different CHAPS concentrations 
The optimal CHAPS concentration for solubilization 
of active VIP and glucagon binding sites was deter- 
mined by incubation of crude pig liver membranes (5 
mg/ml) at different detergent concentrations in the pres- 
ence of 25% glycerol. A concomitant increase of VIP 
and glucagon binding to solubilized proteins was ob- 
served with a maximum binding activity at 0.4% 
CHAPS. At higher detergent concentrations, an inhibi- 
tion of both VIP and glucagon binding was observed. 
An extraction yield of 60-80% was calculated by meas- 
urement of the remaining ligand binding activity of the 
solubilized membranes. The assay of the binding activ- 
ity in the crude solubilized extract was hampered by a 
low ratio of specific to nonspecific binding. 
3.2. DEAE-Sepharose anion-exchange chromatograph? 
of solubilized membrane proteins 
The solubilized membrane extracts were applied to 
DEAE-Sepharose and the eluted fractions were assayed 
for VIP and glucagon binding activities. As shown in 
Fig. 1, several fractions (A, B, C and D) bound [“‘I]VIP 
or/and [“51]glucagon. The binding proteins in fraction 
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Fig. 1. DEAE-Sepharose chromatography of CHAPS-solubilized pig 
liver membranes. Pig liver membrane xtracts, solubilized with 0.4% 
CHAPS, were applied to DEAE-Sepharose (5 x 20 cm). A NaCl gra- 
dient (.... linear 4WOO mM, 750 ml; isocratic 400 mM, 250 ml; linear 
4OG-750 mM, 500 ml) was used for protein elution and fractions of 
12 ml were collected. Aliquots were assayed for [“‘I]VIP (A) and 
[“‘I]glucagon (A) total binding activities as described in section 2 and 
binding is expressed as fmol/ml. Absorbance at 13 = 280 is shown by 
the broken line (---). Fractions used for further studies were named A, 
B. C and D in their eluting order as indicated by the bars. 
A were eluted at 40 mM NaCl buffer, whereas the oth- 
ers required increasing concentrations of NaCl. A VIP 
and glucagon degrading activity was present in fraction 
B. Aliquots (100 ~1) of fraction B were incubated with 
[‘251]VIP or [‘*‘I]glucagon (20 PM) for 2 h at room 
temperature. After trichloroacetic acid (10%) precipita- 
tion and centrifugation (3,000 x g for 15 min), the radi- 
oactivity of the supernatant was determined, as a crude 
index of peptide degradation and corresponded to 50% 
and 58% of the initial radioactivity for glucagon and 
VIP, respectively. When [‘251]glucagon and [‘251]VIP 
were incubated with fraction A, the index of degrada- 
tion was 3% and 21%, respectively. Similar values were 
obtained when the labeled peptides were incubated with 
20 mM Tris-HCl (pH 7.5) buffer only. Both [‘251]VIP 
and [1251]glucagon bi ding activities of fraction C could 
not be inhibited by excess native peptides (5 PM) indi- 
cating that the binding is non-specific. 
3.3. Binding of [125I] VIP and [‘2’I]glucagon to proteins 
of DEAE fractions A and D 
3.3.1. [‘251]VIP binding sites of fraction A 
Concentrations of VIP that induced half-maximal in- 
hibition (IC,,) of [“‘I]VIP binding to fraction A (Fig. 
2A), were 1.8 + 0.5 nM indicating the presence of high- 
affinity VIP binding proteins. A Scatchard plot [22] of 
the competition data and analysis using the ‘Ligand 
program’ [23] indicated the presence of a single high 
affinity site for VIP with a dissociation constant (f&) of 
1.5 + 0.6 nM and a maximum binding site concentra- 
tion (B,,.J of 1.3 k 0.4 pmol/mg. The potency order of 
-10 -9 -8 -7 -6 -5 
[Peptide], log M 
Fig. 2. Inhibition of [‘?]VIP binding to soluble proteins separated by 
DEAE chromatography. Proteins in DEAE fraction A (panel A) and 
fraction D (panel B) were incubated with [‘*‘I]VIP (20 PM) and in- 
creasing concentrations of unlabeled VIP (o), &RF (0), PHI (m). 
secretin (A). VIP(l&28) (0) or glucagon (A). Results are expressed as 
percentage of specific binding, determined as described in section 2, 
in the absence of unlabeled peptides. Each point represents the mean 
of three experiments performed in duphcate. 
peptide inhibition of VIP binding is: VIP > PHI > 
rGRF > secretin (Fig. 2A). 
3.3.2. [“‘I]VIP binding sites of fraction D 
[“‘I]VIP binding to fraction D (Fig. 2B) was inhibited 
by VIP in a dose-dependent manner, but the ICso value 
of 0.7 PM was about 400-fold higher than that obtained 
with fraction A. A different peptide specificity was also 
obtained, the order of potency being rGRF > VIP > 
VIP(lO-28) > secretin > PHI. 
3.3.3. [“‘Ilglucagon binding sites of fraction A 
[‘251]glucagon binding was dose-dependently inhib- 
ited by the extended form of glucagon, oxyntomodulin 
(pig or human), which is almost lOO-fold less potent 
than glucagon (Fig. 3). Neither GLP-l( 17-36) nor 
GLP-2 affected the binding of [‘251]glucagon to fraction 
A. The presence of a single high affinity site for glu- 
cagon (Kd and B,,, values were 0.08 f 0.03 nM and 
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Fig. 3. Inhibition of [“51]glucagon bmdmg to soluble proteins sepa- 
rated by DEAE chromatography. Proteins in DEAE fraction A were 
incubated with [“‘I]glucagon (20 PM) and increasmg concentrations 
of unlabeled glucagon (a), human oxyntomodulin (D), pig oxynto- 
modulin (o), GLP-1(7-36) (A) or GLP-2 (A). Results are expressed as 
percentage of specific binding. determined as described in section 2, 
in the absence of unlabeled peptides. Each point represents the mean 
of three experiments performed m duplicate. 
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Fig. 4. Effect of GTP-y-S on the [“‘I]VIP binding to fraction A from Fig. 5. SDS-PAGE autoradiographs of the low-affinity [‘251]VIP bind- 
DEAE chromatography. Proteins from DEAE fraction A were incu- ing proteins separated by DEAE chromatography. [‘*‘I]VIP was cross- 
bated with 20 pM of [“‘I]VIP with increasing concentrations of GTP- linked with disuccinimidyl suberate to soluble proteins (fraction D) in 
y-S. Data are expressed as percentage of specific binding, determined the presence (+) or the absence (-) of 5 PM VIP. Samples were 
as described in section 2, in the absence of GTP-r-S. Each point is resolved on SDS-PAGE (IO-15% gel). The resulting autoradiographs 
representative of two experiments performed in duplicate. Inset: are shown with the migration position of protein markers (kDa) indi- 
Scatchard plot of VIP binding in the absence (n) or presence (A) of cated on the right and the arrow indicating the molecular masses 
20 PM GTP-y-S. (kDa) of the major labeled proteins. 
0.31 + 0.01 pmol/mg, respectively) was obtained by 
analysis of the competition data of fraction A. 
3.3.4. Effect of GTP-y-S on the [“51]VIP binding 
The non-hydrolyzable GTP analogue. GTP-Y-S, in- 
hibited the [‘251]VIP binding in fraction A in a dose- 
dependent manner and 45% inhibition of binding oc- 
curred at 100 PM (Fig. 4). At this concentration GDP 
had a similar inhibitory effect (40%) while ATP did not 
effectuate binding. Further, competitive binding studies 
in the presence of 20 ,uM GTP-7-S induced a shift in the 
affinity from 1.5 to 6.5 + 1.1 nM (Fig. 4). GTP-y-S, up 
to 100 ,uM, had no inhibitory effect on the [“51]VIP 
binding to fraction D or [‘“51]glucagon binding to frac- 
tion A. 
3.4. SDS-PAGE of [‘251] VIP cross-linked to proteins of 
DEAE fraction D 
Proteins separated by DEAE-chromatography in 
fraction D were cross-linked to [1’51]VIP using disuccin- 
2 
VIP - + 
38 
Volume 3 18, number 1 FEBS LETTERS February 1993 
imidyl suberate and analyzed by SDS-PAGE and au- 
toradiography (Fig. 5). A labeled band corresponding 
to a size of 22 kDa was identified and the labeling 
specifically inhibited by 5 ,uM VIP. 
3.5. PuriJication and characterization of low VIP afJin- 
ity binding sites of the DEAE fraction D 
Fraction D, which unlike the high affinity proteins 
showed no adsorption to wheat-germ-agglutinin aga- 
rose, was further purified by gel filtration, affinity 
chromatography, and a final anion-exchange chromat- 
ographic step on Mono Q. Fractions containing specific 
[‘251]VIP binding were pooled for further processing. A 
single band of protein, with a molecular mass of 18 
kDa, estimated by SDS-PAGE analysis and silver stain- 
ing, was obtained after the final purification step (Fig. 
6). This purification recovered 0.5 mg of this protein 
from the starting 2.4 g of solubilized membrane protein. 
Initial attempts to sequence the protein were unsuccess- 
ful probably due to a blockage of the N-terminal resi- 
due. Two nmol protein was therefore enzymatically hy- 
drolyzed by endoproteinase Lys-C and the resulting 
fragments were separated by reversed phase HPLC. The 
major peak had the sequence of D-G-N-G-Y-I-S-A-A- 
E-L-R-H-V-M-T-N-L-G-E-X-L-T-D-E-E-V-D-E-M-I- 
R-E-A- (X representing an unidentified amino acid) 
which is identical to mammalian calmodulin(95-128). 
The low-affinity VIP binding protein furthermore ex- 
hibited a [1251]VIP binding similar to that of pig brain 
calmodulin. Competitive inhibition of [“‘I]VIP binding 
by native VIP resulted in similar IC,, values, 0.3 PM 
and 0.2 PM, respectively. Also the calmodulin inhibitor, 
calmidazolium inhibited the [‘251]VIP binding to the pu- 
rified protein and calmodulin similarly with an IC,, 
concentration of 2 ,uM. 
4. DISCUSSION 
This simultaneous olubilization and initial purifica- 
tion of VIP and glucagon high affinity binding proteins 
is reported. DEAE-chromatography separated high af- 
finity binding proteins for VIP and glucagon (fraction 
A) from proteins which bound glucagon (fraction B) 
and VIP (fraction D) with a lower affinity. 
The putative VIP and glucagon receptors co-eluted in 
the same fraction (A) with binding activities of 1.3 pmol/ 
mg for VIP and 0.31 pmol/mg for glucagon. Thus, a 
2-fold purification was estimated after the DEAE 
chromatography step with a 3540% yield of VIP and 
glucagon receptors, respectively. The VIP binding sites 
show an affinity for VIP (Kd 1.5 nM) comparable to that 
of the plasma membrane receptor (& 1.7 nM) and have 
a similar peptide specificity: VIP > PHI > rGRF > 
secretin. The affinity of [“‘I]VIP binding protein in frac- 
tion A is reduced by 4-fold with GTP-y-S suggesting 
that it is functionally associated with a G protein. In the 
presence of GTP-y-S the binding affinity (Kd 6.5 nM) 
lo 
IO 
30 40 
Elution time (mm) 
Fig. 6. Purification of low affinity VIP-binding protein (fraction D) 
by anion-exchange chromatography. VIP-binding proteins in fraction 
D were purified by gel filtration and VIP-affinity chromatography and 
concentrated as described in section 2. The sample was injected on a 
Mono Q 515 column equilibrated in 20 mM Tris-HCl, pH 7.0, 0.1% 
CHAPS at a flow rate of 1 ml/min. Bound proteins were eluted with 
a gradient (cl M) NaCl (---) and the elution of the proteins was 
monitored at L 214 nm (--). Inset: the fractions containing [‘251]VIP 
binding activity, indicated by the bar, were pooled and subjected to 
SDS-PAGE analysis. The migration positions of protein markers 
(kDa) are shown on the left of the silver-stained gel and the migration 
of the single band stained is shown on the right. 
of VIP is similar to that of GTP-insensitive VIP-recep- 
tors solubilized from pig liver by Voisin [12]. As in our 
study, high-affinity VIP receptors in solubilized rat liver 
cell membranes maintain their GTP sensitivity [9]. 
The solubilized [“‘I]glucagon binding proteins dis- 
played the same peptide specificity and Kd values (0.08 
nM) as those observed for glucagon receptors in pig 
liver cell membranes (0.12 nM) [24]. Both VIP and glu- 
cagon receptor protein complexes from this DEAE frac- 
tion (A) were found to contain N-acetylglucosamine 
and/or sialic acid residues in agreement with other re- 
ports on hepatic VIP [25] and glucagon [lo] receptors. 
These findings indicate the presence of distinct high 
affinity VIP and glucagon binding proteins in the 
DEAE-purified fraction A. 
The biological significance of VIP binding directly to 
calmodulin is unclear although VIP and VIP(lO-28) 
have been shown to be potent inhibitors (ICso: 0.5 PM) 
of calmodulin stimulation of brain phosphodiesterase 
activity [26]. Further, there is a close association be- 
tween the regulatory roles of calmodulin- and VIP-in- 
duced signal transduction. Indeed, trifluoroperazine 
and an anti-calmodulin serum have been shown to re- 
duce VIP-enhanced adenylate cyclase activity by 70% in 
pituitary adenoma GH,C, cells [27] and calmodulin- 
sensitive adenylate cyclase has been demonstrated in 
several tissues [28]. 
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Further studies are necessary to ascertain if a calmod- 
ulin-like protein can be associated with the VIP recep- 
tors as postulated for insulin receptors, which have been 
suggested to contain a calmodulin-binding domain [29]. 
In conclusion, the simultaneous olubilization of ac- 
tive high affinity VIP and glucagon putative receptors 
has been achieved as well as their separation from other 
VIP and glucagon binding proteins by anion-exchange 
chromatography. Furthermore, the binding of VIP to 
calmodulin in liver cell membranes may suggest that 
calmodulin could be involved in the regulation of VIP 
activity. 
While this manuscript was in preparation. the cloning 
of two nonidentical high-affinity receptors for VIP was 
reported [30,31]. In one of the cases [31], expression of 
receptor mRNA was observed in the liver. Also a report 
appeared according to which a membrane-bound VIP- 
binding protein from guinea pig lung had been identi- 
fied as calmodulin (D. Stallwood et al. (1992) J. Biol. 
Chem. 267, 19617-19621). 
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